Dupilumab, an IL-4Rα antagonist, has demonstrated efficacy across multiple type 2 diseases, including asthma, atopic dermatitis, CRSwNP, and eosinophilic COPD [44,45]. This evidence concerns the gene IL4R and atopic eczema.